Page last updated: 2024-09-04

pomalidomide and Leukemia, Myeloid, Acute

pomalidomide has been researched along with Leukemia, Myeloid, Acute in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ben Amara, A; Benyamine, A; Castanier, C; Castellano, R; Collette, Y; Fauriat, C; Fournié, JJ; Goubard, A; Granjeaud, S; Le Roy, A; Mege, JL; Olive, D; Orlanducci, F; Pont, F; Prébet, T; Riccardi, F; Vey, N1
Foster, MC; Zeidner, JF1
Lentzsch, S; Pan, B1

Reviews

2 review(s) available for pomalidomide and Leukemia, Myeloid, Acute

ArticleYear
Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML).
    Current drug targets, 2017, Volume: 18, Issue:3

    Topics: Clinical Trials as Topic; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Thalidomide; Treatment Outcome

2017
The application and biology of immunomodulatory drugs (IMiDs) in cancer.
    Pharmacology & therapeutics, 2012, Volume: 136, Issue:1

    Topics: Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Second Primary; Thalidomide

2012

Other Studies

1 other study(ies) available for pomalidomide and Leukemia, Myeloid, Acute

ArticleYear
Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.
    Frontiers in immunology, 2018, Volume: 9

    Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents; CD56 Antigen; Cells, Cultured; Cytotoxicity, Immunologic; Genes, MHC Class I; Humans; Immunologic Factors; K562 Cells; Killer Cells, Natural; Lenalidomide; Leukemia, Myeloid, Acute; Male; Mice; Middle Aged; Monitoring, Immunologic; Natural Cytotoxicity Triggering Receptor 3; Thalidomide; Xenograft Model Antitumor Assays

2018